ライフサイエンスコーパス: torsade de pointes

1 nctive polymorphic ventricular tachycardia ('torsades de pointes').

2 ciated arrhythmias (eg, long QT syndrome and torsade de pointes).

3 ome with QT-related ventricular arrhythmias (torsades de pointes).

4 ion of the QT interval and/or development of torsades de pointes).

5 y-high-dose methadone may be associated with torsade de pointes.

6 European market after being associated with torsade de pointes.

7 ary outcome was QT prolongation resulting in Torsade de pointes.

8 sion of atrial arrhythmias, but it can cause torsade de pointes.

9 o prolongs the QT interval but rarely causes torsade de pointes.

10 s, and thus the potential for development of torsade de pointes.

11 h from ventricular arrhythmias, specifically torsade de pointes.

12 interval and an increased propensity toward torsade de pointes.

13 to explain the link between hypokalemia and torsade de pointes.

14 affecting susceptibility to arrhythmias like Torsade de Pointes.

15 o a life-threatening ventricular arrhythmia, Torsade de Pointes.

16 d is a significant predictor of drug-induced torsade de pointes.

17 T syndrome and the lethal cardiac arrhythmia torsade de pointes.

18 at of antiarrhythmic agents known to promote torsade de pointes.

19 may cause abnormal heart rhythms, including torsade de pointes.

20 gned to examine the risk of rare events like torsade de pointes.

21 load, early afterdepolarizations (EADs), and torsade de pointes.

22 ype 2, women are more vulnerable than men to torsade de pointes.

23 QT prolongation with the associated risk of torsade de pointes.

24 redispose individuals to QT prolongation and torsade de pointes.

25 rs), can prolong the QT interval and provoke torsades de pointes.

26 es, which are thought to trigger episodes of torsades de pointes.

27 f repolarization are not capable of inducing torsades de pointes.

28 ar tachycardia displaying characteristics of torsades de pointes.

29 nduce potentially lethal arrhythmia known as torsades de pointes.

30 ally the polymorphic ventricular tachycardia torsades de pointes.

31 predisposes to drug-induced QT prolongation/torsades de pointes.

32 enic afterdepolarizations thought to trigger torsades de pointes.

33 ciated with the potentially fatal arrhythmia torsades de pointes.

34 duced long QT interval syndrome (diLQTS) and torsades de pointes.

35 lead to interventions to reduce the risk of torsades de pointes.

36 sociated with the rare adverse drug reaction torsades de pointes.

37 adverse events including QT prolongation and torsades de pointes.

38 to hyperfunction of L-type channels, such as Torsades de Pointes.

39 quired and drug-induced long QT syndrome and torsades de pointes.

40 ation and is associated with case reports of torsades de pointes.

41 There was 1 episode of nonsustained torsade de pointes (1 of 70, 1.4%) after ibutilide.

42 ons in a cohort of consecutive patients with Torsades de Pointes; (3) the relationship between K(+) c

43 16 cardiac arrests, with one resulting from Torsade de Pointes (6%).

44 enic can prolong the QT interval and lead to torsade de pointes, a life-threatening ventricular arrhy

45 Torsades de pointes, a form of ventricular tachycardia,

46 mary suspect in cases of QTc prolongation or torsade de pointes after dofetilide (a known proarrhythm

47 n in the placebo group (0.3% versus 0.1% for torsade de pointes and 0.9% versus 0.2% for severe neutr

48 The incidences of torsade de pointes and severe neutropenia (absolute neut

49 QT interval, possibly increasing the risk of Torsade de pointes and sudden cardiac death.

50 Prediction of torsade de pointes and sudden death can be improved by e

51 iew the mechanisms and establish the risk of torsade de pointes and sudden death with antipsychotic d

52 nd haloperidol have been documented to cause torsade de pointes and sudden death, the most marked ris

53 cognition of the role of noncardiac drugs in torsade de pointes and sudden death.

54 Another developed sustained torsade de pointes and was treated effectively with dire

55 Macrolides are known to cause torsade des pointes and other ventricular arrhythmias, a

56 ssociated with complex arrhythmias including torsades de pointes and 2 degrees atrioventricular block

57 ndrome, adult women carry a greater risk for Torsades de pointes and sudden cardiac death than do men

58 On the other hand, drug-induced torsades de pointes and symptomatic long QT syndrome hav

59 ments, can result in ventricular arrhythmia (torsade de pointes) and sudden death.

60 eads to polymorphic ventricular tachycardia (torsades de pointes) and sudden death.

61 ncope, polymorphous ventricular tachycardia (torsades de pointes), and sudden arrhythmic death.

62 clinical use is burdened by QT prolongation, torsade de pointes, and sudden cardiac death.

63 n between familial and drug-induced cases of torsade de pointes, and the recognition of the role of n

64 ardiac events defined as syncope, documented torsades de pointes, and aborted cardiac arrest or sudde

65 Cases of QT prolongation, torsades de pointes, and sudden death have been reported

66 QT interval prolongation and torsade de pointes are associated with astemizole intake

67 ced QT(C) prolongation and potentially fatal Torsade de Pointes arrhythmia.

68 of hiPSC-CMs that are associated with lethal Torsade de Pointes arrhythmia.

69 0400 is effective against dofetilide-induced torsade de pointes arrhythmias (TdP), while maintaining

70 Torsade de pointes arrhythmias could be induced during e

71 interval on the electrocardiogram and cause torsade de pointes arrhythmias not by direct block of th

72 is commonly associated with life-threatening torsade de pointes arrhythmias that develop as a consequ

73 ties that have been associated with syncope, torsade de pointes arrhythmias, and sudden cardiac death

74 nterval and predispose to the development of torsade de pointes arrhythmias.

75 el are associated with an increased risk for Torsades des Pointes arrhythmias and sudden death.

76 ontractions and fibrillations reminiscent of Torsades des Pointes arrhythmias, and they exhibit sever

77 se in the intracellular calcium may underlie torsades de pointes associated with intravenous tacrolim

78 There were 2 occurrences of nonfatal torsade de pointes, both in the haloperidol group.

79 patients (50%) had NSVT, including 1 who had torsade de pointes, but most had <5 episodes.

80 that infrequently causes QT-prolongation and torsades de pointes cardiac arrhythmias.

81 lt to predict which patients are at risk for torsade de pointes, careful assessment of the risk to be

82 Consistently in the Torsades de Pointes cohort, concomitant acute infections

83 ENDO, causing a persistent increase in TDR; Torsade de Pointes developed or could be induced only in

84 bradycardia per se, determines the risk for torsade de pointes during atrioventricular block (AVB).

85 nd Europe with diLQTS, defined as documented torsades de pointes during treatment with a QT-prolongin

86 ated in causing QT interval prolongation and torsades de pointes, errors in the use of medications th

87 clinical observation of QT prolongation and torsade de pointes found with astemizole intake may prin

88 They examine the risk for torsade de pointes from antipsychotic drugs and estimate

89 terval prolongation, potassium channels, and torsade de pointes from both the long QT syndrome and dr

90 ars, and cases of prolonged QTc interval and torsades de pointes have been described in HIV-infected

91 icular arrhythmia/tachyarrhythmia in 12, and torsade de pointes in 2 patients).

92 arrhythmias developed in 7 patients (5.8%) (torsade de pointes in 2), significant bradycardia in 20

93 clinical observation of QT prolongation and torsade de pointes in a patient with undetectable serum

94 was a significant predictor of drug-induced torsade de pointes in an independent sample of 216 cases

95 APD(90,) reduced BVR (P<0.01), and abolished torsade de pointes in hearts treated with either 20 nmol

96 o the cell surface cause QT prolongation and torsade de pointes in patients treated with As(2)O(3).

97 , which has been recognized as a hallmark of torsade de pointes in the acquired LQTS, plays a major r

98 to describe the mode of onset of spontaneous torsade de pointes in the congenital long QT syndrome.

99 The in vivo electrophysiologic mechanism of torsade de pointes in the long QT syndrome is described,

100 ervals and higher incidences of drug-induced torsade de pointes in women than in men are incompletely

101 eats after aftercontractions occurred before torsades de pointes in an in vivo dog model of drug-indu

102 s used to examine susceptibility to acquired torsades de pointes in chronic atrioventricular block an

103 voke the life-threatening cardiac arrhythmia torsades de pointes in some, but not all, individuals.

104 proved predictors of risk for progression to torsade de pointes, in addition to the degree of QT prol

105 ing of noncardiac medications known to cause torsades de pointes, including fluoroquinolones and intr

106 Monthly reports of QTc prolongation or torsade de pointes increased from a mean of 0.3 (95% CI,

107 A common effect of many drugs producing torsade de pointes is block of the rapidly activating co

108 The risk of torsade de pointes is low in hospitalized patients with

109 ion of the QT interval and the occurrence of torsades de pointes is similar to more expensive alterna

110 The progression to torsade de pointes may be less related to degree of QT p

111 cially amiodarone, and drugs associated with torsade de pointes may have contributed to poor outcomes

112 dult gender differences in propensity toward torsade de pointes may reflect the relatively greater pr

113 c ventricular tachycardia, Brugada syndrome, torsades de pointes) may result in serious consequences,

114 over, the data suggest that cisapride caused torsade de pointes not only by blocking IKr but also by

115 Torsade de pointes occurred after an abrupt acceleration

116 Two cases of torsade de pointes occurred, 1 on day 2 and the other on

117 longation after ibutilide, only 1 episode of torsade de pointes occurred.

118 Torsades de pointes occurred in 1 patient (0.1%) with CO

119 /31; 61%) versus WT (8/26; 31%; P<0.05), and Torsades de Pointes occurred more frequently (73% Cav3.1

120 Torsade de pointes often occurs with underlying hypokale

121 nic atrioventricular block animals exhibited torsades de pointes on dofetilide, the arrhythmia was in

122 is no evidence to suggest that this leads to torsade de pointes or sudden death.

123 None of the patients on sotalol developed Torsade de pointes or sustained ventricular arrhythmias.

124 rhythmia was not VT storm, and no history of torsades de pointes or QT interval prolongation.

125 ychloroquine+/-azithromycin, no instances of Torsade de pointes, or arrhythmogenic death were reporte

126 entified 24 patients with QT prolongation or torsade de pointes, or both, associated with protease in

127 entricular tachycardia, ventricular flutter, torsade de pointes, or ventricular fibrillation.

128 netheless, drug-induced long QT syndrome and torsade de pointes pose unique challenges for clinicians

129 en identified in a patient with drug-induced torsade de pointes precipitated by the IKr blocker cisap

130 All drugs that cause torsade de pointes prolong the QTc interval and bind to

131 s system vasculitis and leukoencephalopathy, torsades de pointes, pulmonary vasculopathy, and pulmona

132 g class IC drugs, patients with low risk for torsades de pointes receiving selected class III agents,

133 The patient suffered recurrent runs of torsade de pointes, refractory to aggressive medical man

134 Drug-induced QT prolongation and torsades de pointes remain significant and often unpredi

135 The incidence of torsade de pointes remains unknown.

136 ind QT prolongation to be common (24%), with Torsade de Pointes representing 6% of in-hospital cardia

137 icited seizure was followed by an episode of torsade de pointes requiring immediate cardioversion.

138 A set of drugs with known clinical torsade de pointes risk was selected to develop and cali

139 l prolongation in hospitalized patients with torsades de pointes risk factors.

140 some drug-induced arrhythmias, particularly torsades de pointes, risk factors are well defined.

141 Torsades de Pointes score was relatively high with ibuti

142 The risk of torsades de pointes should be assessed in patients who a

143 rhythmic agent with the propensity to induce torsades de pointes, substantially inhibits the current.

144 5 micromol/L totally suppressed spontaneous torsade de pointes (TdP) and reduced the vulnerable wind

145 or inherited and acquired long-QT associated torsade de pointes (TdP) arrhythmias, and sympathetic di

146 e market because of its propensity to induce torsade de pointes (TdP) arrhythmias.

147 Dose-dependent susceptibility to Torsade de Pointes (TdP) by class III drug dofetilide, 3

148 tricular tachycardia with characteristics of torsade de pointes (TdP) developed in the presence of dl

149 hat women are more prone than men to develop torsade de pointes (TdP) in a defined cohort of patients

150 Female rabbit hearts are more susceptible to torsade de pointes (TdP) in acquired long QT type 2 than

151 functional electrical instability leading to torsade de pointes (TdP) in LQTS are poorly understood.

152 repolarization (TDR) and the development of Torsade de Pointes (TdP) in models of LQT1, LQT2 and LQT

153 ation (TDR) may be related to the genesis of torsade de pointes (TdP) in patients with the long-QT (L

154 ural dispersion of repolarization (TDR), and torsade de pointes (TdP) induced by beta-adrenergic agon

155 Drug-related torsade de pointes (TdP) is usually recognized within da

156 The ventricular arrhythmia torsade de pointes (TdP) occurs after QT interval prolon

157 ationary reentry, giving rise to the typical torsade de pointes (TDP) pattern.

158 ion of repolarization (TDR) and induction of torsade de pointes (TdP) under conditions mimicking the

159 rigins of EADs and the mechanisms underlying Torsade de Pointes (TdP) were investigated in a model of

160 Extrasystolic activity and spontaneous torsade de pointes (TdP) were never observed, and stimul

161 ion (EAD) in producing a trigger to initiate torsade de pointes (TdP) with QT prolongation induced by

162 that the calmodulin inhibitor W-7 suppresses torsade de pointes (TdP) without shortening the QT inter

163 induced long-QT syndromes (diLQTS) can cause torsade de pointes (TdP), a life-threatening ventricular

164 iac repolarization and increases the risk of Torsade de Pointes (TdP), a potentially lethal arrhythmi

165 SIDS), one with documented prolonged QTc and Torsade de Pointes (TdP), and in an adult woman with QTc

166 proarrhythmic risk and in particular risk of Torsade de Pointes (TdP), as indicated by prolongation o

167 trioventricular block, T-wave alternans, and torsade de pointes (TdP).

168 h a twisting QRS morphology, better known as torsade de pointes (TdP).

169 and to be associated with the development of torsade de pointes (TdP).

170 ntially life-threatening arrhythmia known as Torsade de Pointes (TdP).

171 llation population despite its known risk of Torsade de pointes (TdP).

172 ngation yet absent proarrhythmia markers for Torsade de Pointes (TdP).

173 T, n = 18 123) and VA (n = 29 193) including torsade de pointes (TdP, n = 8163) reporting for 663 ant

174 Torsades de pointes (TdP) +/-2 degrees atrioventricular

175 cteristic of long QT syndrome (LQTS) include torsades de pointes (TdP) and/or 2 degrees atrioventricu

176 healthy subjects and may be associated with torsades de pointes (TdP) arrhythmia, we tested the hypo

177 teria that are associated with initiation of torsades de pointes (TdP) in patients with acquired (a-)

178 oal of this study was to identify markers of torsades de pointes (TdP) in patients with drug-associat

179 e used for AF, excessive QT prolongation and torsades de pointes (TdP) often occur shortly after sinu

180 nse to hERG ion channel specific blocker was Torsades de Pointes (TdP) reentrant arrhythmia activatio

181 factors associated with azimilide-associated torsades de pointes (TdP) ventricular tachycardia.

182 eed for dose adjustment and the incidence of torsades de pointes (TdP) were identified.

183 a higher risk of lethal arrhythmias, called Torsades de pointes (TdP), compared to the opposite sex.

184 QT-prolonging medications with known risk of torsades de pointes (TdP), which is associated with high

185 or for acquired long-QT syndrome (aLQTS) and torsades de pointes (TdP).

186 oth syndromes can result in life-threatening torsades de pointes (TdP).

187 safety, including the risk of drug-induced 'torsades de pointes' (TdP) arrhythmia, is a major concer

188 Women have a higher incidence of torsades de pointes than men, but it is not known if the

189 and some patients present with short-coupled torsade de pointes, the genetics of which are poorly und

190 ac conduction disorders, or risk factors for torsade de pointes, there have been no serious cardiovas

191 QT-prolonging medications can predispose to torsades de pointes, there is a relative paucity of info

192 een shown to correlate with a higher risk of torsades de pointes, there is no established threshold b

193 ine can induce acquired long QT syndrome and torsade de pointes through its interaction with the Purk

194 creates the substrate for the development of torsade de pointes under long-QT conditions.

195 it is not known if the risk of drug-induced torsades de pointes varies during the menstrual cycle.

196 Torsade de pointes ventricular tachyarrhythmia in the lo

197 on of the action potential and propensity to torsade de pointes ventricular tachycardia.

198 There were no cases of torsades de pointes, ventricular fibrillation, or polymo

199 Twelve documented cases of torsade de pointes VT were noted.

200 sustained ventricular tachycardia (VT), and torsade de pointes VT) in the antiarrhythmic drug arm of

201 The incidence of torsade de pointes was 0.6% at five years (95% confidenc

202 Documentation of the onset of torsade de pointes was available for 15 patients.

203 Pause-dependent torsade de pointes was clearly documented in 14 of the 1

204 The primary outcome of torsade de pointes was not observed in the entire popula

205 The primary outcome of torsade de pointes was observed in 1 (0.015%) out of 647

206 iac death was recorded in five patients, and torsade de pointes was recorded in seven other patients.

207 When a drug associated with torsades de pointes was prescribed to a patient at moder

208 ons occurred due to QTc prolongation, and no Torsades de Pointes was reported.

209 arrest and 379 cases of QTc prolongation or torsade de pointes were associated with methadone.

210 fety end points, including the occurrence of torsade de pointes, were evaluated.

211 ent with relapsed APL developed asymptomatic torsade de pointes, which resolved spontaneously and did

212 The characteristic association of torsade de pointes with T-wave alternans and short-long

213 ly fatal polymorphic ventricular tachycardia torsade de pointes, with drugs or other environmental st